Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
Top Cited Papers
Open Access
- 16 September 2004
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351 (12), 1206-1217
- https://doi.org/10.1056/nejmoa040431
Abstract
Available treatments for hepatitis B e antigen (HBeAg)–negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications.Keywords
This publication has 32 references indexed in Scilit:
- Long–Term Suppression of Hepatitis B E Antigen–Negative Chronic Hepatitis B by 24–Month Interferon TherapyHepatology, 2003
- Cerebral dysfunction in chronic hepatitis C infectionJournal of Viral Hepatitis, 2003
- Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR AssayJournal of Clinical Microbiology, 2002
- Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?Hepatology, 2001
- Hepatitis B e antigen-negative chronic hepatitis BHepatology, 2001
- The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis BJournal of Hepatology, 2001
- Peginterferon-??-2a (40kD)Drugs, 2001
- The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis BHepatology, 2000
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology, 1999
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995